While the CEO of Transgene aspires to launch their product independently in Europe, he acknowledges the immense cost of a Phase 3 trial. A partnership with a large pharmaceutical company is viewed as the most realistic "best case scenario" to accelerate development and de-risk the final, most expensive stage.

Because their platform generates more high-potential drug targets than they can pursue internally, the company frames partnerships with large pharmaceutical firms as an ethical imperative. This approach ensures novel findings don't languish, allowing them to become life-saving drugs while triggering revenue sharing for their community partners.

Over 20 years, Alnylam raised $7.5 billion. Remarkably, this was evenly split between equity financing from capital markets and non-dilutive funding from pharmaceutical partnerships. This balanced strategy was essential for financing a long, capital-intensive R&D journey while managing shareholder dilution.

Major firms like Merck employ varied deal structures to build pipelines. Merck's $6.7 billion all-upfront acquisition of Terns for a Phase 1-2 asset contrasts with its Quotient collaboration, which has a small $20 million upfront but $2.2 billion in discovery-stage milestones. This highlights a flexible approach to risk and reward.

Contrary to the focus on large upfront payments, a smarter partnership strategy is to negotiate for a larger share of downstream success through royalties and milestones. This can yield far greater long-term returns if the product succeeds.

While its internal pipeline targets oncology, LabGenius partners with companies like Sanofi to apply its ML-driven discovery platform to other therapeutic areas, such as inflammation. This strategy validates the platform's broad applicability while securing non-dilutive funding to advance its own assets towards the clinic.

Beyond developing its own drug portfolio, Monterosa strategically leverages its discovery platform for partnerships with companies like Roche and Novartis. These deals have provided over $300 million in non-dilutive capital, funding operations without giving away equity.

The partnership for their drug Respiratide was structured with a unique incentive. Protagonist can choose to opt out of a co-promote deal, which triggers a $400M payment from Takeda and elevates their potential future milestones and royalty rates significantly (up to 29%). This provides strategic flexibility and non-dilutive capital.

Neurix's deals with Sanofi and Gilead involve the partner funding early development through human proof-of-concept, minimizing Neurix's upfront financial risk. Crucially, the deal structure allows Neurix to "opt-in" for a 50/50 profit share in the U.S. later, retaining significant upside on successful programs.